A bacterial active material responsive to colon cancer microenvironment and its preparation method and application

By constructing hybrid materials between bacteria and Cu2O, responding to H2S in the colon cancer microenvironment and generating CuS, combining E. H. Huo's metabolizing lactic acid to generate short-chain fatty acids, the problems of poor accuracy and off-targeting effects in the existing technology are solved, and the problem of poor accuracy and off-targeting effects are achieved Highly effective and low-toxic anti-tumor treatment.

CN116139173BActive Publication Date: 2024-11-22WUHAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211104154.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-09
Publication Date
2024-11-22
Estimated Expiration
2042-09-09

AI Technical Summary

Technical Problem

The prior art is difficult to accurately respond to the colon cancer microenvironment, effectively clear H2S and inhibit tumor angiogenesis. Traditional treatments have poor accuracy and off-targeting effects, making it difficult to achieve efficient and low-toxic anti-tumor efficacy.

Method used

By encapsulating hyaluronic acid on the Cu2O precursor and combining with Ebacillus Huo, hybrid materials of bacteria and Cu2O are constructed using electrostatic action, and in response to H2S triggering CuS generation in the colon cancer microenvironment, chemical kinetic therapy is achieved, combined with Ebacillus Huo metabolizes lactic acid to produce short-chain fatty acids, which inhibits tumor growth in both directions.

Benefits of technology

It improves the targeting accuracy of the therapeutic agent, reduces off-target toxic side effects, realizes a multi-modal cascade reaction, produces efficient and low-toxic anti-tumor efficacy, and significantly inhibits the growth and angiogenesis of colon cancer tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116139173B_ABST
    Figure CN116139173B_ABST
Patent Text Reader

Abstract

The present invention discloses a bacterial active material that responds to the microenvironment of colon cancer, and a preparation method and application thereof. The method comprises: wrapping hyaluronic acid on a Cu2O precursor to obtain a Cu2O precursor with a negative surface charge; modifying the surface of Eubacterium hallii with polyacrylamine hydrochloride to obtain a Eubacterium hallii solution with a positive surface charge; combining the Cu2O precursor with a negative surface charge and the Eubacterium hallii solution with a positive surface charge through electrostatic action to obtain a hybrid material of bacteria and the Cu2O precursor. The material can accurately respond to the microenvironment of colon cancer, remove H2S, metabolize lactic acid, and in situ generate CuS with a chemokinetic therapeutic effect, thereby realizing a multi-mode cascade reaction, thereby producing an anti-tumor therapeutic effect with high efficiency and low side effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a bacterial active material responsive to a colon cancer microenvironment, and a preparation method and application thereof. Background Art

[0002] Selective overexpression of cystathionine-β-synthase (CBS) in colorectal cancer can promote the generation of endogenous H2S (0.3-3.4 mM) in the colorectal cancer environment. As the main gaseous transmitter of colorectal cancer, H2S plays an important role in the occurrence and deterioration of colorectal cancer, such as promoting the proliferation of colorectal cancer cells, stimulating tumor vascular relaxation and angiogenesis, and cell bioenergetics. At the same time, the typical metabolic characteristic of cancer cells is that glucose is rapidly converted into lactate through the Warburg effect, and then lactate is secreted into the extracellular space, thereby forming a tumor microenvironment rich in lactate. However, lactate in the tumor microenvironment is closely related to the occurrence and development of cancer, such as accelerated tumor metastasis, tumor recurrence, immunosuppression, and poor treatment effect. Given the fact that H2S supports tumor growth, effectively removing the effect of H2S in the colorectal cancer microenvironment will be an innovative strategy to inhibit colorectal cancer. However, most reports only use overexpressed endogenous H2S in the colorectal cancer microenvironment as a trigger to activate fluorescent probes for colorectal cancer diagnosis, rather than precise treatment. In addition, some studies have used H2S-activated photothermal agents for colorectal cancer treatment, but this does not prevent the off-target effects of photothermal therapy from damaging normal tissues. Therefore, effectively eliminating H2S in the colorectal cancer microenvironment, inhibiting tumor angiogenesis, and achieving a therapeutic cascade reaction are major challenges in the treatment of colorectal cancer. At the same time, short-chain fatty acids (SCFAs) including acetic acid (Ace), propionic acid (Pro), isobutyric acid (Iso-but), butyric acid (But), isovaleric acid (Iso-val), valeric acid (Val) and hexanoic acid (Hex) can inhibit tumor growth to a certain extent. In particular, butyric acid has a significant anti-cancer effect, which can induce cancer cell differentiation, apoptosis and inhibit cancer cell proliferation without inhibiting the growth of normal cells.

[0003] Given the specificity of the colon cancer microenvironment, it is particularly important to accurately respond to the colon cancer microenvironment to achieve accurate tumor treatment. Traditional tumor therapeutic agents have the defects of poor precision and single treatment mode. Therefore, it is necessary to provide a bacterial active material that responds to the colon cancer microenvironment. Summary of the invention

[0004] The purpose of the present invention is to provide a bacterial active material that responds to the colon cancer microenvironment and its preparation method and application. The material can accurately respond to the colon cancer microenvironment, remove H2S, metabolize lactic acid, and in situ produce CuS with chemokinetic therapeutic effects, thereby achieving a multimodal cascade reaction, thereby producing a highly efficient anti-tumor therapeutic effect with low side effects.

[0005] In a first aspect of the present invention, a method for preparing a bacterial active material responsive to a colon cancer microenvironment is provided, the method comprising:

[0006] The Cu2O precursor is coated with hyaluronic acid to obtain a Cu2O precursor with negative surface charge;

[0007] The surface of Eubacterium hallii is modified with polyacrylamine hydrochloride to obtain a surface positively charged Eubacterium hallii solution;

[0008] The surface negatively charged Cu2O precursor and the surface Eubacterium hallii solution are combined through electrostatic action to obtain a hybrid material of bacteria and Cu2O precursor.

[0009] Furthermore, the Cu2O precursor is synthesized by inside-out growth, specifically comprising:

[0010] Precursor liquid Cu(NO3)2·3H2O and polyvinylpyrrolidone (PVP) are dispersed in water and stirred, and then hydrazine hydrate N2H4·H2O is added and stirred continuously, and then centrifuged and washed to obtain nanoparticles, namely the Cu2O precursor.

[0011] Furthermore, the mass ratio of the precursor liquid Cu(NO3)2·3H2O to the PVP is (1-1.5):(0.8-1.2), and the mass fraction of the N2H4·H2O is 30-40wt%.

[0012] Furthermore, the process of wrapping the Cu2O precursor with hyaluronic acid to obtain the Cu2O precursor with negative surface charge comprises:

[0013] Add hyaluronic acid to the Cu2O precursor to react in the dark, then centrifuge and wash to obtain a Cu2O precursor with negative surface charge.

[0014] Furthermore, the concentration of the hyaluronic acid is 0.5-2.5 mg / mL. The mass ratio of the Cu2O precursor to the hyaluronic acid is (5-50):(1-10).

[0015] Furthermore, the method of modifying the surface of Eubacterium hallii with polyacrylamine hydrochloride to obtain a surface positively charged Eubacterium hallii solution comprises:

[0016] adding an aqueous solution containing Eubacterium hallii into an aqueous solution containing polyacrylamine hydrochloride, mixing the mixture, centrifuging and washing the mixture, and obtaining a surface positively charged Eubacterium hallii solution;

[0017] Wherein, the bacterial colony count in the aqueous solution containing Eubacterium hallii is 10 7 ~10 9CFU / mL, the concentration of the aqueous solution containing polyacrylamine hydrochloride is 20-60 mg / mL, and the volume ratio of the aqueous solution containing Eubacterium hallii to the aqueous solution containing polyacrylamine hydrochloride is (0.1-4):(1-2).

[0018] Furthermore, the surface negatively charged Cu2O precursor and the surface positively charged Eubacterium hallii solution are combined by electrostatic action to obtain a bacteria-Eubacterium hallii hybrid active material, comprising:

[0019] Ultrasonic dispersion of the negatively charged Cu2O precursor in a PBS solution, and then adding the positively charged Eubacterium hallii solution, mixing, centrifuging and washing to obtain a hybrid active material of bacteria and Cu2O precursor;

[0020] The mass volume ratio of the surface negatively charged Cu2O precursor, the PBS solution and the surface positively charged Eubacterium hallii solution is: (5-15) mg: 8 mL: (0.4-3.2) mL, and the pH of the PBS solution is 7.4.

[0021] In the second aspect of the present invention, a bacterial active material responsive to the colon cancer microenvironment prepared by the method is provided.

[0022] In the third aspect of the present invention, there is provided the use of the bacterial active material responsive to the colon cancer microenvironment in the preparation of anti-tumor preparations.

[0023] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:

[0024] 1. The present invention provides a bacterial active material that responds to the colon cancer microenvironment. Eubacterium hallii (E. hallii) can specifically metabolize lactic acid to produce favorable short-chain fatty acids (SCFAs). Eubacterium hallii and Cu2O precursors are integrated through electrostatic interactions to construct a Bac@Cu2O biomodulator that responds to the colon cancer microenvironment. By combining the Cu2O precursor with Eubacterium hallii, the targeting accuracy of the therapeutic agent can be effectively improved under the drive of active bacteria, and off-target toxic side effects can be reduced. At the same time, the metabolism of Eubacterium hallii can target the consumption of lactic acid accumulated in the colon cancer microenvironment, produce short-chain fatty acids, and inhibit the growth of colon cancer tumors in both directions.

[0025] 2. The present invention organically combines Eubacterium hallii and Cu2O hybrid active materials; triggers the dissociation between the two by responding to the highly expressed H2S in the colon cancer microenvironment, and forms CuS to achieve tumor inhibition effects such as chemodynamic therapy. Specifically: the generated Bac@Cu2O biomodulator of the colon cancer microenvironment uses the tendency instinct of E. hallii to actively target the tumor site, thereby consuming lactic acid and overexpressed H2S in the colon microenvironment and improving the colon tumor microenvironment. At the same time, the consumption of endogenous H2S weakens tumor angiogenesis and also produces CuS. CuS mediates Fenton-like reactions to produce ·OH to achieve chemodynamic therapy. In these cascade reactions, as Cu 2+ The conversion to Cu+, the antioxidant GSH is also effectively depleted, further amplifying the oxidative stress of ·OH, thereby enhancing chemodynamic therapy. This multimodal combined therapy not only combines the advantages of each single therapy, but also makes up for their respective deficiencies, thereby producing a highly efficient and low-toxic anti-tumor effect, achieving "1+1>2" enhanced tumor treatment efficacy. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0027] Figure 1 To construct the Bac@Cu2O hybrid therapeutic system and its anti-tumor mechanism; Figure 1 A is the construction process; Figure 1 B is a schematic diagram of tumor targeting; Figure 1 C is the anti-tumor mechanism.

[0028] Figure 2 For the characterization of Bac@Cu2O hybrid active materials; Figure 2 A- Figure 2 C is the morphology and size of the Cu2O precursor and its combination with bacteria; Figure 2 D is the element mapping distribution of Bac@Cu2O; Figure 2 E is the surface potential change before and after Eubacterium hallii modified PAH and Cu2O precursor modified HA; Figure 2 F is the characterization of Cu2O precursor that can consume H2S to form CuS using transmission electron microscopy (TEM); Figure 2 G is the crystal structure of Cu2O precursor and CuS characterized by powder X-ray diffraction (XRD).

[0029] Figure 3 To characterize the CuS-mediated chemical dynamics reaction; Figure 3 A is the ultraviolet absorption peak of ·OH produced by CuS under different conditions evaluated by methylene blue (MB). Figure 3 B is the change of ultraviolet absorption peak of antioxidant GSH consumed by CuS at different concentrations;

[0030] Figure 4 The cytotoxicity and lactate consumption capacity of Bac@Cu2O hybrid active materials; Figure 4 A is the result that the bioactive material Bac@Cu2O has a strong killing effect on CT26 tumor cells; Figure 4 B is the lactic acid consumption result; Figure 4 C is the result of the formation of short-chain fatty acids; Figure 4 D: Confocal microscopy characterization of H2S consumption.

[0031] Figure 5 The tumor targeting ability and biocompatibility of Bac@Cu2O hybrid active materials in mice; Figure 5 A is the tumor targeting enrichment result; Figure 5 B and Figure 5 C is the result of in vivo biosafety analysis.

[0032] Figure 6 The in vivo antitumor effect of Bac@Cu2O hybrid active materials; Figure 6 A is the average tumor volume during treatment; Figure 6 B is the weight change of mice during the treatment period; Figure 6 C is the change in individual tumor volume during treatment; Figure 6 D is the measurement results of lactic acid, short-chain fatty acids and endogenous hydrogen sulfide in tumor tissue after treatment. DETAILED DESCRIPTION

[0033] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0034] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0035] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or obtained by existing methods.

[0036] The embodiment of the present invention provides a bacterial active material that responds to the colon cancer microenvironment. The overall idea is as follows:

[0037] According to a typical embodiment of the present invention, a method for preparing a bacterial active material responsive to a colon cancer microenvironment is provided, the method comprising:

[0038] S1. Coating hyaluronic acid on a Cu2O precursor to obtain a Cu2O precursor with negative surface charge;

[0039] The preparation method of the Cu2O precursor is simple, the process is simple, and the operability is high. The Cu2O precursor can consume H2S and is a nanoformulation that can respond to the tumor microenvironment.

[0040] As an optional embodiment, the Cu2O precursor is synthesized by inside-out growth, specifically comprising: dispersing the precursor liquid Cu(NO3)2·3H2O and polyvinyl pyrrolidone (PVP) in water and stirring, then adding hydrazine hydrate N2H4·H2O and continuing to stir, then centrifuging and washing to obtain nanoparticles, i.e., the Cu2O precursor. The mass ratio of the precursor liquid Cu(NO3)2·3H2O to the PVP is (1-1.5): (0.8-1.2), and the mass fraction of the N2H4·H2O is 30-40wt%.

[0041] As a specific implementation manner, a hyaluronic acid aqueous solution is added to the Cu2O precursor to react in the dark, followed by centrifugation and washing to obtain a Cu2O precursor with negative surface charge.

[0042] The concentration of the hyaluronic acid aqueous solution is 0.5-2.5 mg / mL. The mass ratio of the Cu2O precursor to the hyaluronic acid aqueous solution is (5-50):(1-10).

[0043] If the concentration of the hyaluronic acid is less than 0.5 mg / mL, the amount of hyaluronic acid modified on the surface of Cu2O is too little and the Cu2O is still easily oxidized; if the concentration is greater than 2.5 mg / mL, the Cu2O is easily agglomerated and the dispersibility is poor, which is not conducive to hybridization with bacteria.

[0044] S2, modifying the surface of Eubacterium hallii with polyacrylamine hydrochloride to obtain a surface positively charged Eubacterium hallii solution;

[0045] In step S2, an aqueous solution containing Eubacterium hallii is added to an aqueous solution containing polyacrylamine hydrochloride, mixed, and then centrifuged and washed to obtain a surface positively charged Eubacterium hallii solution;

[0046] Wherein, the bacterial colony count in the aqueous solution containing Eubacterium hallii is 10 7 ~10 9CFU / mL, the concentration of the aqueous solution containing polyacrylamine hydrochloride is 20-60 mg / mL, and the volume ratio of the aqueous solution containing Eubacterium hallii to the aqueous solution containing polyacrylamine hydrochloride is (0.1-4):(1-2).

[0047] If the number of bacterial colonies in the aqueous solution containing Eubacterium hallii is less than 10 7 CFU / mL, the concentration of Eubacterium hallii is too low, which is not conducive to the effective loading of bacteria on nanocarriers, thereby reducing the therapeutic effect; if it is greater than 10 9 CFU / mL, the amount of polyacrylamine hydrochloride modified on the bacterial surface is too little, and the surface positive charge is weak, which is not conducive to combining with the negatively charged Cu2O precursor through electrostatic interaction;

[0048] If the concentration of the aqueous solution containing polyacrylamine hydrochloride is less than 20 mg / mL, the polyacrylamine hydrochloride modified on the bacterial surface is too little, the surface positive charge is weak, and it is not conducive to combining with the negatively charged Cu2O precursor through electrostatic action; if it is greater than 60 mg / mL, it leads to excessive modified polyacrylamine hydrochloride, thereby affecting the bacterial activity;

[0049] The volume ratio of the aqueous solution containing Eubacterium hallii to the aqueous solution containing polyacrylamine hydrochloride is (0.1-4): (1-2) because within this ratio range, bacteria modified with polyacrylamine hydrochloride can be obtained without affecting the activity of the bacteria. If the volume ratio is too small or too large, it is not conducive to obtaining ideal bacteria modified with polyacrylamine hydrochloride.

[0050] As an optional embodiment, the preparation method of the aqueous solution containing E. hallii is as follows: E. hallii is cultured anaerobically in DSMZ 110 medium (containing: 0.5 g / mL ground beef particles) at 37°C overnight. When the bacteria grow to a stationary phase, the culture medium containing the bacteria is taken, centrifuged (6000 rpm, 5 min) to collect the bacteria, then resuspended with sterile PBS and centrifuged again, repeated three times, and the bacteria are dispersed in water for standby use.

[0051] The purchased bacterial agent of Eubacterium hallii (E. hallii) has a deposit number of (DSM 3353 or ATCC 27751).

[0052] S3, combining the surface negatively charged Cu2O precursor and the surface Eubacterium hallii solution through electrostatic action to obtain a hybrid material of bacteria and Cu2O precursor.

[0053] The step S3 specifically includes:

[0054] Ultrasonic dispersion of the negatively charged Cu2O precursor in a PBS solution, and then adding the positively charged Eubacterium hallii solution, mixing, centrifuging and washing to obtain a hybrid active material of bacteria and Cu2O precursor;

[0055] The mass volume ratio of the surface negatively charged Cu2O precursor, the PBS solution and the surface positively charged Eubacterium hallii solution is: (5-15) mg: 8 mL: (0.4-3.2) mL, and the pH of the PBS solution is 7.4.

[0056] The mass volume ratio of the surface negatively charged Cu2O precursor, the PBS solution and the surface positively charged Eubacterium hallii solution is: (5-15) mg: 8 mL: (0.4-3.2) mL. The reason is that under this mass volume ratio condition, Bac@Cu2O biohybrid active materials with good morphology and function can be prepared; adding too little or too much of the surface negatively charged Cu2O precursor and adding too little or too much of the surface positively charged Eubacterium hallii solution will not be conducive to the preparation of ideal Bac@Cu2O biohybrid active materials, resulting in too much or too little Cu2O precursor for functional modification of bacterial surface, or affecting the biological activity of the bacteria themselves;

[0057] According to another typical embodiment of the present invention, a bacterial active material responsive to the colon cancer microenvironment prepared by the method is provided.

[0058] According to another typical embodiment of the present invention, there is provided the use of the bacterial active material responsive to the colon cancer microenvironment as an anti-tumor drug.

[0059] like Figure 1 As shown in the figure, the anti-tumor mechanism is to first utilize the anaerobic instinct of E.haill to actively enrich Bac@Cu2O at the tumor site. Then, the H2S overexpressed in the colon microenvironment and Cu2O undergo a sulfurization reaction to promote the disintegration of the hybrid material, and the bacterial metabolism of lactic acid in the microenvironment produces short-chain fatty acids to achieve colon cancer treatment. The consumption of endogenous H2S and the generation of CuS mediate the Fenton-like reaction to produce toxic OH, and H2S can weaken tumor angiogenesis. And in the cascade reaction process, with the Cu 2+ Cu + The antioxidant GSH is also effectively depleted by the conversion of ·OH, further amplifying the oxidative stress of ·OH, thereby enhancing chemodynamic therapy. In conclusion, lactate-short-chain fatty acid-mediated metabolic therapy combined with H2S scavenging-induced chemodynamic therapy provides a new tumor microenvironment-tailored therapeutic strategy for colon cancer treatment.

[0060] This "targeting-metabolic regulation-multimodal combined therapy" strategy driven by active life forms overcomes the defects of traditional nanotherapeutics, such as poor precision and single treatment mode, and provides efficient and precise targeted treatment for tumors.

[0061] The bacterial active material responsive to the colon cancer microenvironment of the present application will be described in detail below in combination with examples and experimental data.

[0062] Example 1 Preparation method of Eubacterium hallii combined with Cu2O precursor

[0063] (1) Cu(NO3)2·3H2O (1.208 g) and PVP (1.0 g) were dispersed in 50 mL of water and stirred for 30 min. Then, hydrazine hydrate N2H4·H2O (35 wt%) was added and stirred for 1 h. After centrifugation and washing, a Cu2O precursor with regular morphology and size was obtained.

[0064] (2) The 20 mg Cu2O precursor obtained in the above (1) was uniformly dispersed in 50 mL of aqueous solution and ultrasonicated for 10 min to fully disperse it. Subsequently, 5 mL of aqueous solution containing hyaluronic acid (10 mg) was added to the above Cu2O precursor dispersion and stirred at room temperature for 24 h. After the reaction was completed, centrifugation (12000 rpm, 10 min), water washing, and collection of precipitation were performed to obtain HA-coated nanoparticles Cu2O@HA.

[0065] (3) E. hallii was cultured anaerobically in DSMZ 110 medium (containing 0.5 g / mL ground beef) at 37°C overnight. When the bacteria grew to the stationary phase, the culture medium containing the bacteria was collected by centrifugation (6000 rpm, 5 min), then resuspended in sterile PBS and centrifuged again. After repeating this process three times, the bacteria were dispersed in water for later use.

[0066] (5) Then, 5 mL of aqueous solution containing bacteria (~10 8 CFU / mL) was added to 1 mL of an aqueous solution (50 mg / mL) containing poly(propyleneamine hydrochloride) (PAH), gently vortexed for one minute, centrifuged (6000 rpm, 5 min), and washed three times with water to collect the bacteria with PAH coated on the surface (Bac@PAH).

[0067] (6) 10 mg of Cu2O@HA obtained in (2) was ultrasonically dispersed in 5 mL of aqueous solution, and then 2 mL of Bac@PAH aqueous solution was added thereto. The mixture was vortexed for 3 min, centrifuged (6000 rpm, 5 min), and washed with PBS three times to collect the hybrid active material (Bac@Cu2O) combined with bacteria and Cu2O.

[0068] Experimental Example 1 Structural characterization and performance testing of Bac@Cu2O hybrid active materials

[0069] Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were used to characterize the morphology and size of the Cu2O precursor and its combination with bacteria; Figure 2 As shown in AD, the changes in the morphology, size, and element mapping of the Cu2O precursor and its combination with bacteria indicate the successful preparation of the active material. Dynamic scattering (DLS) was used to measure the potential changes of the prepared Cu2O precursor and its combination with bacteria to determine whether the surface modification of the material was successful; Figure 2 As shown in E, the potential changes before and after the modification of PAH by Eubacterium hallii and the modification of HA by Cu2O precursor further prove that the active material can be prepared by electrostatic adsorption. Transmission electron microscopy (TEM) was used to characterize that the Cu2O precursor can consume H2S to form CuS. Powder X-ray diffraction (XRD) characterized the crystal structure of Cu2O precursor and CuS; Figure 2 As shown in Figure F, the successful synthesis of Cu2O precursor and CuS was confirmed. In addition, the change of the ultraviolet absorption peak of methylene blue (MB) at 665nm characterized the CuS-mediated chemical reaction. Figure 3 As shown in A and B, the ultraviolet absorption peak of methylene blue (MB) at 665 nm is significantly reduced in the presence of CuS and H2O2, indicating that CuS can effectively produce ·OH to mediate the chemical reaction and can also effectively consume GSH.

[0070] Application Example 1 In vitro application of Bac@Cu2O hybrid active materials

[0071] In vitro co-culture experiments were carried out using CT26 tumor cells and the prepared Bac@Cu2O active materials to systematically study the in vitro anti-tumor properties of these active living biomaterials.

[0072] Tumor cytotoxicity. First, CT26 cells were seeded in 24-well plates (3 × 10 4 cells / well) were cultured in 1640RPMI medium for 24 hours. To verify that Eubacterium hallii can selectively consume lactate in the culture environment to metabolize and produce short-chain fatty acids such as butyrate, the bioactive material Bac@Cu2O was co-cultured with CT26 cells in the presence of lactate and H2S for 24 hours, and then 20μL MTT was added and incubated for 4 hours. The absorbance at a wavelength of 540nm was measured using an enzyme reader. The toxicity of different materials to CT26 tumor cells was determined. Figure 4As shown in A, the bioactive material Bac@Cu2O has a strong killing effect on CT26 tumor cells, and the cell survival rate is less than 15%, indicating that Bac@Cu2O can effectively consume lactate and H2S in the culture environment, produce butyrate and CuS to achieve metabolic therapy and chemodynamic therapy.

[0073] Lactate consumption and short-chain fatty acid formation. First, CT26 cells were seeded in 24-well plates (3 × 10 4 The bioactive material Bac@Cu2O was co-cultured with CT26 cells under lactic acid culture conditions for 24 h, and then the lactic acid content in the culture medium was determined using a lactic acid kit. Figure 4 As shown in B, the lactic acid content in the culture medium was significantly reduced in the group with the presence of Eubacterium hallii, indicating that it can effectively consume lactic acid. At the same time, the content of short-chain fatty acids in the culture medium after co-culture was measured, and it was found that the butyric acid content was significantly increased, indicating that the cells can metabolize lactic acid to produce butyric acid and achieve metabolic treatment.

[0074] H2S consumption. First, CT26 cells were seeded in 6-well plates (2×10 5 The cells were cultured in 1640 RPMI medium for 24 h. 100 μM H2S was added for 6 h, and then different bioactive materials were added to co-culture with CT26 cells for 4 h. The H2S content in the cells was characterized by the H2S probe WSP-5. Figure 4 As shown in D, the intracellular H2S content was significantly reduced in the group cultured with Cu2O, indicating that it can remove H2S.

[0075] Application Example 2 In vivo tumor targeting ability and biocompatibility of Bac@Cu2O hybrid active materials

[0076] The present invention uses Balb / c mice as model animals to construct a CT26 tumor-bearing mouse model, and systematically studies the tumor targeting ability and biocompatibility of active materials in vivo after tail vein injection; including:

[0077] (1) Tumor Targeting Enrichment

[0078] When the mouse tumor grew to 120 mm 3 When the Cy5.5-labeled Bac, Cu2O@HA, Bac+Cu2O@HA, and Bac@Cu2O (Bac: 1×10 8CFU, Cu2O: 5 mg / kg) biomaterials were injected into mice through the tail vein, and the anesthetized mice were placed in the Maestro in vivo fluorescence imaging system (CRI, Woburn, MA, USA) for observation at the predetermined time points (0, 2, 4, 6, 8, 12, 24 h). Figure 5 A. As time goes by, the bioactive material Bac@Cu2O has obvious fluorescence at the tumor site, and the fluorescence intensity gradually increases, indicating that bacteria can play a targeted role and carry Cu2O accurately to the colon cancer tumor tissue.

[0079] (2) Biosafety Analysis

[0080] Comprehensively evaluate various indicators of the mouse body after material treatment, including blood biochemical analysis, immunotoxicity, biocompatibility, etc., to detect the biosafety of the hybrid material constructed by the present invention in vivo and its clinical application potential. Figure 5 As shown in B and C, after the injection of bioactive materials, the various indicators of the mice were not significantly different from those of the normal control mice, indicating that the bacterial active biomaterials have good biosafety and clinical application potential in vivo.

[0081] Application Example 3 Study on the anti-tumor performance of Bac@Cu2O hybrid active materials in vivo

[0082] The present invention uses Balb / c mice as model animals to construct a CT26 tumor-bearing mouse model and systematically studies the therapeutic effect of hybrid materials on tumors after tail vein injection. 3 At the same time, the tumor-bearing mice were randomly divided into groups, and the corresponding materials were injected into the mice through the tail vein on the 1st, 3rd, 6th and 9th days. The changes in the weight of the mice (measured by a balance) and the size of the tumor (measured by a vernier caliper with the long diameter (L) and short diameter (W) of the tumor) were recorded every two days, and the tumor volume was calculated using the Still formula: V = W2 × L / 2. After the treatment, the mice were killed and all tumors were collected to measure lactic acid, short-chain fatty acids and endogenous hydrogen sulfide.

[0083] like Figure 6As shown in AB, compared with other control materials (control materials include Control (PBS), Bac, Cu2O@HA and Bac+Cu2O@HA), after tumor-bearing mice were treated with the bioactive material Bac@Cu2O, the growth of the tumor was significantly inhibited, and the volume of the tumor was significantly smaller than that of other materials, indicating that the Bac@Cu2O hybrid material can effectively inhibit the growth of colon cancer tumors and has good anti-tumor efficacy. At the same time, the lactic acid, short-chain fatty acids and endogenous hydrogen sulfide of the tumor tissue after the treatment were measured. The results showed that after the treatment of the bioactive material Bac@Cu2O, lactic acid was significantly reduced, butyric acid was significantly increased, and hydrogen sulfide was also significantly reduced, which further indicated that the bioactive material Bac@Cu2O can respond to the colon cancer microenvironment and transform harmful substances into tumor therapeutic agents to achieve metabolic therapy and chemodynamic therapy.

[0084] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0085] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0086] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A method for preparing a bacterial active material that responds to the colon cancer microenvironment, characterized in that: The method comprises: The Cu2O precursor is coated with hyaluronic acid to obtain a Cu2O precursor with negative surface charge; The surface of Eubacterium hallii is modified with polyacrylamine hydrochloride to obtain a surface positively charged Eubacterium hallii solution; The surface negatively charged Cu2O precursor and the surface Eubacterium hallii solution are combined by electrostatic action to obtain a hybrid material of bacteria and Cu2O precursor; The Cu2O precursor is synthesized by inside-out growth, specifically comprising: Precursor liquid Cu(NO3)2·3H2O and polyvinyl pyrrolidone are dispersed in water and stirred, and then hydrazine hydrate N2H4·H2O is added and stirred continuously, and then centrifuged and washed to obtain nanoparticles, namely the Cu2O precursor.

2. The method for preparing a bacterial active material responsive to the colon cancer microenvironment according to claim 1, characterized in that: The method of wrapping the Cu2O precursor with hyaluronic acid to obtain a Cu2O precursor with negative surface charge comprises: Hyaluronic acid is added to the Cu2O precursor to react in the dark, followed by centrifugation and washing to obtain a Cu2O precursor with negative surface charge.

3. The method for preparing a bacterial active material responsive to the colon cancer microenvironment according to claim 2, characterized in that: The concentration of the hyaluronic acid is 0.5-2.5 mg / mL.

4. The method for preparing a bacterial active material responsive to the colon cancer microenvironment according to claim 1, characterized in that: The method of modifying the surface of Eubacterium hallii with polyacrylamine hydrochloride to obtain a surface positively charged Eubacterium hallii solution comprises: adding an aqueous solution containing Eubacterium hallii into an aqueous solution containing polyacrylamine hydrochloride, mixing the mixture, centrifuging and washing the mixture, and obtaining a surface positively charged Eubacterium hallii solution; Wherein, the bacterial colony count in the aqueous solution containing Eubacterium hallii is 10 7 ~10 9 CFU / mL, the concentration of the aqueous solution containing polyacrylamine hydrochloride is 20-60 mg / mL, the volume ratio of the aqueous solution containing Eubacterium hallii to the aqueous solution containing polyacrylamine hydrochloride is (0.1-4):(1-2), and the molecular weight of polyacrylamine hydrochloride is 3-600K.

5. The method for preparing a bacterial active material responsive to the colon cancer microenvironment according to claim 1, characterized in that: The surface negatively charged Cu2O precursor and the surface positively charged Eubacterium hallii solution are combined by electrostatic action to obtain a hybrid material of bacteria and Cu2O precursor, comprising: Ultrasonic dispersion of the negatively charged Cu2O precursor in a PBS solution, and then adding the positively charged Eubacterium hallii solution, mixing, centrifuging and washing to obtain a hybrid material of bacteria and the Cu2O precursor; The mass volume ratio of the negatively charged Cu2O precursor, the PBS solution and the positively charged Eubacterium hallii solution is (5-15) mg: 8 mL: (0.4-3.2) mL, and the pH of the PBS solution is 7.

4.

6. A bacterial active material responsive to the colon cancer microenvironment prepared by the method according to any one of claims 1 to 5.

7. Use of the bacterial active material responsive to the colon cancer microenvironment according to claim 6 in the preparation of anti-colon cancer preparations.